Navigation Links
Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials

focus is to evaluate a drug's safety, including safe dosage range. Phase Ib studies are typically combinations of the new agent plus a standard agent.

The Translational Oncology Program (TOP) was founded in 2004 following a request from physicians affiliated with US Oncology to establish an early phase study program. TOP is comprised of a select group of US Oncology physicians who address standard Phase I study design and select Phase II studies. Members of the US Oncology Research Network met with investigators in January 2005 and TOP began its first study two months later. The program's goals include establishing a Phase I research infrastructure, eventually incorporating targeted therapy into its research efforts.

"What's exciting is that as TOP has evolved, the US Oncology Research Network has taken on more Phase I and II trials that are typically the newest, and often, the most novel approaches to cancer treatment that will ultimately benefit our patients," said Jeffery Nieves, Pharm D., Director or the Translational Oncology Program for the US Oncology Research Network.

"Early-stage trials conducted in a smaller, community setting can result in a speedier determination of a new agent's viability, eventually bringing new therapies to patients quicker."

Each TOP site is required to have a dedicated physician, research nurse and investigational/research pharmacist who have the experience and credentials to conduct phase I trials. In addition, each site must meet facility and equipment requirements to participate in early-stage trials.

TOP rounds are conducted weekly at each site and include an assessment of patient status and safety for all participants, a review of pending and priority protocol status, and discussion of new scientific concepts. In 2007, the 200th patient was accrued to a TOP trial.

About US Oncology Research

The US Oncology Research Network is an established community-based research operation spec
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:11/26/2014)... 26, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... and Drug Administration (FDA) has issued a Complete ... for AVP-825. AVP-825 is an investigational drug-device combination ... utilizing a novel Breath Powered delivery technology. ... consistent with the preliminary feedback announced on November ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... 2012   SAP America Inc., a subsidiary ... SAP ), today introduced the SAP® Collaborative E-Care ... several modules, the application aims to connect care providers, patients ... was made at HIMSS 2012 , being held February ...
... Feb. 21, 2012 SurgLine International, Inc. (SGLN.PK). ... ("SurgLine") stated, "Over the past six months we have ... business arrangements, distribution contracts and a pending acquisition in ... continued progress. Our management team has ...
Cached Medicine Technology:Newsbyte: SAP to Integrate Healthcare in the Community Through Collaborative Care 2SurgLine International, Inc. Update to Shareholders on Revenue Pipeline and Organizational Changes 2
(Date:11/27/2014)... News) -- Thanksgiving meals can pose a challenge for ... expert says. Many traditional Thanksgiving dishes -- such ... are gluten-free, but "when it comes to pies, stuffing, ... Dr. Anca Safta, director of the Gluten and Allergic ... in North Carolina, said in a center news release. ...
(Date:11/27/2014)... November 27, 2014 The founders of VIM ... comfortable and high functioning compression socks, are proud to announce ... use an innovative Gradient Pressure (TM) knitting technology that is ... VIM & VIGR’s commitment to adding flair and style to ... functional recently caught the eye of a writer at ...
(Date:11/27/2014)... NV (PRWEB) November 27, 2014 Now ... shopping season has officially launched, Emassagechair.com has ... Cyber Monday Discount Event. , Negotiating on behalf ... with top massage chair brands, Emassagechair.com has generated significant ... best deals and biggest discounts yet. , Shoppers are ...
(Date:11/27/2014)... Two international trainers and lecturers on the ... one person with significant needs but limited means obtain ... Mamaly Reshad of the Anacapa Dental Art Institute in ... devoted to helping dentist learn about using All-on-4™ dental ... devoted to helping a patient who has damaged or ...
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “Wekho” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review ... locations instead of people. , An interesting new way to ... iOS and Android devices. It’s called Wekho and it’s ...
Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2
... Steven Reinberg HealthDay Reporter , TUESDAY, Aug. 31 ... vegetables and low in saturated fats can significantly lower ... blood pressure, Johns Hopkins University researchers say. The ... to Stop Hypertension) -- was designed to lower blood pressure ...
... leading cause of cancer deaths worldwide, and the prognosis ... the incidence of one type of lung cancer, adenocarcinoma, ... of the changes in tumor cell biology that result ... abnormal mass of tissue) that have been completely surgically ...
... eight hours of sleep per night have greater risks of ... anxious symptoms, according to a study in the Sept. 1 ... average self-reported nightly sleep duration of eight to nine hours ... sleep durations of less than eight hours and psychological distress ...
... can expedite the communication of urgent findings and improve ... issue of the Journal of the American College ... practice in the United States is moving toward 24/7 ... such as computed tomography (CT) and magnetic resonance imaging ...
... the importance for women with a family history of breast or ... and BRCA2 genes that make them more likely to develop lethal ... The study, which will be published in the Sept. 1 issue ... shows women with the gene live longer and nearly eliminate their ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, Aug. ... has issued a strong policy statement directed toward pediatricians, parents ... and children are getting about sex from television, the Internet ... and the Media , was published online Aug. 30 and ...
Cached Medicine News:Health News:'DASH Diet' Shown to Lower Heart Attack Risk Almost 20% 2Health News:'DASH Diet' Shown to Lower Heart Attack Risk Almost 20% 3Health News:Tumor budding identified as predictor for unfavorable outcome in lung cancer 2Health News:Study links shorter sleep durations with greater risks of mental distress in young adults 2Health News:Study links shorter sleep durations with greater risks of mental distress in young adults 3Health News:Staggered radiologist work shifts improve patient care, study suggests 2Health News:Preventive cancer surgeries save women's lives 2Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 2Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 3
... The AtheNA Multi-Lyte Test System* is ... to simultaneously perform multiple assays from ... well. It offers a simple and ... testing, providing improved clinical sensitivity and ...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... For loading gel sample slots 0.4 mm ... Uses disposable, flexible, autoclavable, precision tapered polycarbonate ... does not contact sample. Includes 6 ... and one plastic spacer. ...
The Pipetman Large-Volume Kit includes two large-volume pipettes conveniently packaged with filters and tips at an exceptional price....
Medicine Products: